Omnicell (OMCL) Q4 2025 earnings review
Titan XT Launch Can't Mask Booking Decline
Omnicell closed FY25 with a mixed report. While total revenue grew 7% for the year and 2% in Q4, the company is visibly struggling with the conclusion of its previous product cycle. Product bookings contracted 4% YoY as the 'XT upgrade cycle' enters late stages. While ARR grew 10% to $636M, demonstrating a successful pivot toward recurring revenue, profitability took a step back in Q4 with EBITDA margins compressing ~340bps YoY. The introduction of Titan XT is the critical bridge to FY26, but guidance implies a growth deceleration to ~4% next year.
🐂 Bull Case
The strategic pivot is working. Annual Recurring Revenue (ARR) grew ~10% YoY to $636M, now comfortably exceeding Product Bookings ($535M). This provides a higher floor for earnings stability regardless of hardware cycles.
Management aggressively cleaned up the balance sheet, repaying $175M in convertible debt and buying back $78M in stock during FY25. Debt levels are manageable, and shareholder yield is active.
🐻 Bear Case
Product bookings fell 4% YoY to $535M. With the XT upgrade cycle largely done and the new Titan XT just launching, the company faces an execution gap. FY26 guidance implies sluggish 4% growth, suggesting Titan XT won't trigger an immediate boom.
Despite revenue growth, Q4 Non-GAAP EBITDA dropped to $37M (11.8% margin) from $46M (15.1% margin) a year ago. Q1 2026 guidance implies further compression to ~9.8% at the midpoint.
⚖️ Verdict: ⚪
Neutral. The transition to recurring revenue is the saving grace here, but the core hardware business is contracting (Bookings down 4%). The Titan XT launch is promising but unproven, and margin compression in Q4 is a red flag that efficiency gains are stalling.
Key Themes
Bookings Deterioration
Decelerating. The most significant leading indicator, Product Bookings, fell 4% YoY to $535M for the full year. Management cited the 'late stage of the XT upgrade cycle.' This indicates a potential revenue gap in future quarters unless the new Titan XT system ramps immediately to fill the void.
Titan XT Product Cycle
Management announced the launch of Titan XT, a next-gen dispensing system. This is the company's answer to the fading XT upgrade cycle. Success here is mandatory to reverse the -4% bookings trend. Unlike previous iterations, this system targets nursing efficiency, attempting to expand the value proposition beyond the pharmacy.
Service Revenue Resilience
Accelerating. Q4 Service revenues grew nearly 8% YoY ($134M vs $125M), outpacing Product revenue growth. This segment now accounts for ~43% of total revenue. As the installed base grows, this high-margin recurring stream is becoming the primary stabilizer of the P&L.
Profitability Squeeze
Reversing. After a year of focus on efficiency, Q4 showed a sharp reversal in profit metrics. Non-GAAP EBITDA fell 20% YoY ($37M vs $46M) despite higher revenue. The guidance for Q1 2026 ($27M-$33M EBITDA) suggests this pressure will persist into the new year, potentially due to launch costs for Titan XT or lingering tariff headwinds mentioned in previous quarters.
Other KPIs
Decelerating. Down 4% from $558M in FY24. This metric measures the health of the hardware pipeline and indicates shrinking demand for the legacy XT product line.
Down significantly from $369M a year ago, but driven by capital allocation rather than burn. The company deployed cash to repay $175M in debt and repurchase $78M in shares. Operating cash flow remained positive at $127M for the year.
Stable Growth. Up ~10% YoY. The company is successfully converting its business model; recurring sources now exceed transactional product bookings.
Guidance
Decelerating. The midpoint ($1.235B) implies roughly 4.2% growth, down from 7% growth in FY25. This reflects the drag from lower bookings in FY25.
Stable. The midpoint ($152.5M) implies ~9% growth over FY25's $140M. While growth is positive, the margin expansion is minimal (approx 12.3% implied margin vs 11.8% in FY25).
Decelerating. The midpoint ($305M) implies -2.8% sequential decline from Q4, though roughly flat to slightly down year-over-year compared to Q4's run rate. This reflects typical seasonality.
Stable. The midpoint ($535M) is flat vs FY25 ($535M). This confirms management does not expect Titan XT to immediately drive a V-shaped recovery in hardware demand.
Key Questions
Titan XT Adoption Curve
With Product Bookings guided flat for FY26, are you anticipating Titan XT to merely replace fading XT demand, or is there a scenario where it drives net expansion in the second half?
Margin Compression Drivers
Q4 EBITDA margins compressed significantly YoY (15.1% to 11.7%). How much of this is one-time launch costs for Titan XT versus structural pressure or tariff impacts previously discussed?
Supply Chain & Tariffs Update
In previous quarters, tariff headwinds were quantified at ~$15M for FY25. Are these fully annualized in the FY26 guidance, and have mitigation efforts (pricing/sourcing changes) fully offset the impact yet?